.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Merck
Farmers Insurance
Cantor Fitzgerald
Baxter
Novartis
US Army
Julphar
Healthtrust
QuintilesIMS

Generated: November 21, 2017

DrugPatentWatch Database Preview

ALTACE Drug Profile

« Back to Dashboard

What is the patent landscape for Altace, and when can generic versions of Altace launch?

Altace is a drug marketed by King Pharms Llc and King Pfizer and is included in two NDAs. There is one patent protecting this drug.

This drug has forty-six patent family members in thirty-one countries and three supplementary protection certificates in three countries.

The generic ingredient in ALTACE is ramipril. There are nineteen drug master file entries for this compound. Thirty-four suppliers are listed for this compound. Additional details are available on the ramipril profile page.
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
King Pharms Llc
ALTACE
ramipril
CAPSULE;ORAL019901-001Jan 28, 1991ABRXYesNo► Subscribe► Subscribe ► Subscribe
King Pfizer
ALTACE
ramipril
TABLET;ORAL022021-003Feb 27, 2007DISCNYesNo► Subscribe► Subscribe ► Subscribe
King Pharms Llc
ALTACE
ramipril
CAPSULE;ORAL019901-004Jan 28, 1991ABRXYesYes► Subscribe► Subscribe ► Subscribe
King Pfizer
ALTACE
ramipril
TABLET;ORAL022021-004Feb 27, 2007DISCNYesNo► Subscribe► Subscribe ► Subscribe
King Pharms Llc
ALTACE
ramipril
CAPSULE;ORAL019901-002Jan 28, 1991ABRXYesNo► Subscribe► Subscribe ► Subscribe
King Pharms Llc
ALTACE
ramipril
CAPSULE;ORAL019901-003Jan 28, 1991ABRXYesNo► Subscribe► Subscribe ► Subscribe
King Pfizer
ALTACE
ramipril
TABLET;ORAL022021-002Feb 27, 2007DISCNYesNo► Subscribe► Subscribe ► Subscribe
King Pfizer
ALTACE
ramipril
TABLET;ORAL022021-001Feb 27, 2007DISCNYesNo► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ALTACE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
King Pfizer
ALTACE
ramipril
TABLET;ORAL022021-002Feb 27, 2007► Subscribe► Subscribe
King Pfizer
ALTACE
ramipril
TABLET;ORAL022021-001Feb 27, 2007► Subscribe► Subscribe
King Pharms Llc
ALTACE
ramipril
CAPSULE;ORAL019901-004Jan 28, 1991► Subscribe► Subscribe
King Pharms Llc
ALTACE
ramipril
CAPSULE;ORAL019901-001Jan 28, 1991► Subscribe► Subscribe
King Pfizer
ALTACE
ramipril
TABLET;ORAL022021-004Feb 27, 2007► Subscribe► Subscribe
King Pharms Llc
ALTACE
ramipril
CAPSULE;ORAL019901-002Jan 28, 1991► Subscribe► Subscribe
King Pharms Llc
ALTACE
ramipril
CAPSULE;ORAL019901-002Jan 28, 1991► Subscribe► Subscribe
King Pfizer
ALTACE
ramipril
TABLET;ORAL022021-004Feb 27, 2007► Subscribe► Subscribe
King Pharms Llc
ALTACE
ramipril
CAPSULE;ORAL019901-003Jan 28, 1991► Subscribe► Subscribe
King Pharms Llc
ALTACE
ramipril
CAPSULE;ORAL019901-003Jan 28, 1991► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ALTACE

Country Document Number Estimated Expiration
CroatiaP20020170► Subscribe
Bulgaria65474► Subscribe
Norway20020978► Subscribe
New Zealand517468► Subscribe
Canada2488370► Subscribe
World Intellectual Property Organization (WIPO)0115674► Subscribe
Ukraine88265► Subscribe
China1268331► Subscribe
South Africa200201470► Subscribe
Czech Republic300687► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ALTACE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB98/047United Kingdom► SubscribePRODUCT NAME: COMBINATIONS OF RAMIPRIL, OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF, AND FELODIPINE, OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF.; REGISTERED: SE 13596 19970919; SE 13597 19970919; UK 00017/0402 19980825; UK 00017/0403 19980825
80030Netherlands► SubscribePRODUCT NAME: FELODIPINE, DESGEWENST IN DE VORM VAN FYSIOLOGISCH AANVAARDBAAR ZOUT, EN (2S, 3AS, 6AS)-1-[(S)-N-[(S)-1-CARBOXY-3-FENYLPROPYL]A LANYL]OCTAHYDROCYCLOPENTA[B]-PYRROOL-2-CARBONZUUR (RAMIPRILAAT) , DESGEWENST IN DE VORM VAN EEN .....ZIE VERDER IN HET DOSSIER; NAT. REGISTRATION NO/ DATE: RVG 22449, RVG 22450 19980618; FIRST REGISTRATION: SE 13596, 13597 19970919
C0001Belgium► SubscribePRODUCT NAME: FELODIPINUM + RAMIPRILUM; NATL. REGISTRATION NO/DATE: 354 IS 373 F 3 19981103; FIRST REGISTRATION: SE 13597 19970919
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Teva
Covington
US Army
Dow
Argus Health
Fish and Richardson
Harvard Business School
Merck
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot